Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Stock price
Equities
002864
CNE1000032C9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 40.37 CNY | +1.64% | -4.18% | +4.07% | |
| Sales 2023 * | 1.15B 160M | Sales 2024 * | 1.47B 204M | Capitalization | 4.25B 591M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | 3,68x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2,90x |
| P/E ratio 2023 * | - | P/E ratio 2024 * | - | Employees | 935 |
| Yield 2023 * | 0,50% | Yield 2024 * | 0,50% | Free-Float | 59.64% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.64% | ||
| 1 week | -4.18% | ||
| Current month | -2.65% | ||
| 1 month | -4.02% | ||
| 3 months | +19.47% | ||
| 6 months | -9.04% | ||
| Current year | +4.07% |
1 week
39.60
41.98
1 month
39.6045.73
Current year
32.4551.57
1 year
32.4551.57
3 years
21.0076.66
5 years
21.0076.66
10 years
12.0481.36
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Lin Xie
CEO | Chief Executive Officer | 55 | 2013 |
Feng Ming Zhu
DFI | Director of Finance/CFO | 52 | 2013 |
Jie Wu
BRD | Director/Board Member | 53 | 2013 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Lin Xie
CEO | Chief Executive Officer | 55 | 2013 |
Shui Pin Zhang
BRD | Director/Board Member | 58 | 2013 |
Xiao Feng Xie
BRD | Director/Board Member | 47 | 2013 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 40.37 | +1.64% | 2,252,300 |
| 23-12-07 | 39.72 | -1.51% | 1,839,996 |
| 23-12-06 | 40.33 | -1.30% | 2,654,334 |
| 23-12-05 | 40.86 | -2.01% | 2,283,097 |
| 23-12-04 | 41.7 | -1.02% | 2,250,400 |
End-of-day quote Shenzhen Stock Exchange, December 07, 2023
More quotes
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent drugs. The Company's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The Company also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The Company is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The Company distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-21
- Q4 2023 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
40.37CNY
Average target price
41.72CNY
Spread / Average Target
+3.34%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.07% | 593 M $ | |
| +63.47% | 538 B $ | |
| +42.56% | 430 B $ | |
| -12.58% | 372 B $ | |
| -7.63% | 264 B $ | |
| -6.49% | 263 B $ | |
| -12.81% | 232 B $ | |
| +1.35% | 198 B $ | |
| -9.77% | 197 B $ | |
| -43.83% | 163 B $ |
